Provides a methodological overview of using guinea pig and spontaneously hypertensive rat models for preclinical screening of cardiovascular drugs.
These models aid preclinical CV drug screening; leaves open human translation and clinical relevance.
Arrhythmias arise as the result of either disorders of cardiac impulse formation or disorders of impulse conduction, or a combination of both. Screening methods have been developed to produce experimental arrhythmias and to select compounds on the basis of their ability to prevent or to reverse these arrhythmias. In this unit, cardiac glycosides are used produce arrhythmias (premature ventricular contractions, then sustained ventricular tachycardia and ventricular fibrillation) and can be used to detect the arrhythmogenic/antiarrhythmic potential of compounds in the guinea pig. The antihypertensive effects of compounds may be assessed using relatively simple in vivo techniques which are adapted to primary screening. The spontaneously hypertensive rat (SHR) model requires no surgery or pharmacological agent to induce hypertension, and it is sensitive to most of the clinically active antihypertensive drugs. The SHR method described in this unit can be used to detect the antihypertensive potential of compounds
No takes yet. Share an insight, caveat, or question.
Lacroix et al. (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: